Back to Hub

FDA PDUFA Complete Response Letter (CRL) Valuation Crater.

Diagnoses the devastating equity destruction events that occur when the FDA rejects a drug approval (CRL) and mandates a new 3-year Phase III trial, forcing a punitive toxic dilution raise.

## The Binary Catalyst Nightmare

The biotech sector is the casino of the stock market. A company can spend 10 years and $500M developing a drug. It all culminates on the FDA's 'PDUFA' target action date. The FDA issues either an Approval or a Complete Response Letter (CRL - Rejection). It is a pure binary coin flip.

### FAQ

**Q: Why do biotech stocks crash 80% in one day?**
A: If the FDA rejects the drug and demands a new 3-year trial to study side effects, the biotech company fundamentally does not have enough cash in their bank account to pay scientists for another 3 years. Wall Street knows the company must issue a massive, dilutive secondary stock offering to raise emergency funds. The stock craters instantly because the existing equity gets mathematically wiped out by the impending flood of new shares.